Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Istradefylline - Kyowa Kirin

Drug Profile

Istradefylline - Kyowa Kirin

Alternative Names: Istradefylline - Kyowa Hakko Kirin; KW-6002; NOURIANZ; Nouriast

Latest Information Update: 25 Dec 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kyowa Hakko
  • Developer Kyowa Kirin
  • Class Antidepressants; Antiparkinsonians; Neuroprotectants; Small molecules; Xanthines
  • Mechanism of Action Adenosine A2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Parkinson's disease
  • Discontinued Major depressive disorder; Restless legs syndrome; Substance-related disorders

Most Recent Events

  • 25 Jul 2021 Committee for Medicinal Products for Human Use (CHMP) adopts a negative opinion for istradefylline for Parkinson’s disease
  • 25 Apr 2020 Efficacy and adverse events data from a phase III trial in Parkinson's disease presented at the 72nd Annual Meeting of the American Academy of Neurology (AAN-2020)
  • 31 Dec 2019 Preregistration for Parkinson's disease in European Union (PO) (Kyowa Kirin pipeline, December 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top